GlaxoSmithKline plc Q2 2025 Earnings Recap

GSK reported robust Q2 2025 results, with group sales increasing by 6%, core operating profit up 12%, and core earnings per share rising 15%, largely driven by strong performance in Specialty Medicines and vaccines.

Key Takeaways

• Specialty Medicines sales surged 15%, contributing significantly to overall revenue growth.
• Three FDA approvals achieved year-to-date support GSK’s R&D momentum and pipeline expansion.
• Cash generation was strong, with GBP 3.7 billion generated in the first half, enabling continued investments and shareholder return strategies.
• The company is reaffirming guidance for 2025, now projected toward the higher end of expectations due to strong operational performance.
• A significant share buyback program is underway, with over GBP 800 million completed since February.